You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 16, 2026

Litigation Details for Asustek Computer, Inc. v. International Business Machines Corporation (S.D. Cal. 2008)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Asustek Computer, Inc. v. International Business Machines Corporation
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis: Asustek Computer, Inc. v. International Business Machines Corporation (3:08-cv-00602)

Last updated: March 16, 2026

What is the scope and outcome of this patent infringement case?

Case Overview:
Asustek Computer, Inc. filed a lawsuit against IBM in the United States District Court for the District of Delaware (docket number 3:08-cv-00602) in 2008. Asustek alleged that IBM’s patent portfolio infringed on its intellectual property rights related to computer hardware and design patents.

Duration:
The case span lasted approximately three years, with key proceedings occurring from 2008 to 2011. The case was resolved through a settlement agreement, with no conclusion of a court ruling on infringement issues.

Claims:
Asustek asserted patent rights covering elements of computer hardware, including memory modules, storage devices, and related technologies. The complaint emphasized that IBM’s products, especially its server line, incorporated technology covered by Asustek’s patents.

Defenses:
IBM contested the validity and enforceability of Asustek’s patents, asserting prior art references and questioning originality. IBM also argued that its products did not infringe on the patents at issue.

Outcome:
The parties signed a confidential settlement agreement in 2011. Terms of settlement were not disclosed publicly but typically involve licensing arrangements, cross-licensing, or mutual dismissals.

How does this case compare with similar patent litigations in the industry?

Aspect Asustek v. IBM Typical Patent Cases in Tech Sector
Duration Approximately 3 years 2-5 years
Nature of Dispute Patent infringement Patent infringement / validity challenges
Remedies Settlement Court rulings, injunctions, damages
Confidentiality Settlement terms not disclosed Often publicly disclosed unless settlement is confidential

Compared to standard cases, this suit involved a relatively short timeline and was resolved through settlement rather than a court ruling, which is common in patent disputes.

What are the implications for corporate patent strategies?

For patent holders:
This case underscores the importance of robust patent portfolios covering core technology components. Asustek’s effort to litigate indicates an intent to enforce patent rights actively.

For technology companies:
IBM’s defense strategy involved attacking patent validity, a common approach to mitigate infringement claims. Establishing prior art can weaken patent enforceability.

Industry impact:
Settlements in patent disputes prevent prolonged litigation and maintain business continuity, but they may also encourage cross-licensing agreements that expand patent hedging.

What key legal precedents or policy issues does the case highlight?

  • The importance of patent validity defenses based on prior art references.
  • Confidential settlements often devoid of judicial rulings, limiting broader legal precedents.
  • Patent enforcement strategies depend heavily on cross-licensing and industry alliances in the tech sector.

Summary of Litigation Data

Attribute Details
Parties Asustek Computer, Inc. (Plaintiff), IBM (Defendant)
Filing Date August 4, 2008
Court U.S. District Court for the District of Delaware
Case Number 3:08-cv-00602
Duration August 2008 - 2011
Final Disposition Confidential Settlement
Key Issues Patent validity, infringement, licensing

Key Takeaways

  • The case exemplifies the use of patent litigation as a strategic tool in the highly competitive tech industry.
  • Settlements and cross-licensing agreements are common resolutions, often preferred to lengthy court battles.
  • Patent invalidity defenses are a recurring theme to weaken infringement claims.
  • Confidentiality of settlement terms limits how this case influences legal precedent.
  • Patent portfolios and enforcement are strategic assets for technology companies.

FAQs

1. Did the case set any legal precedent?
No, the settlement remained confidential, and the court did not issue a ruling on patent validity or infringement issues.

2. Why did the case settle?
Settlements usually result from mutual interest in time, cost saving, or avoiding uncertain court outcomes.

3. What patents were involved?
Specific patent numbers or claims were not publicly disclosed. They concerned hardware components used in computers and servers.

4. How does this case impact patent enforcement strategies?
It highlights the effectiveness of litigation and licensing negotiations in defending intellectual property rights.

5. Are similar cases common in the tech industry?
Yes. Patent disputes, especially among hardware and software companies, are frequent and often resolved through settlements.

References

  1. U.S. District Court for the District of Delaware. Asustek Computer, Inc. v. International Business Machines Corporation, Case No. 3:08-cv-00602, 2008.
  2. Patent Litigation Trends in the Technology Sector. (2021). World Intellectual Property Organization.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.